Division of Roivant Sciences Inc.
Latest From Cytovant Sciences
A review of biopharma start-up dealmaking and financing activity from October through December 2019, based on data from Strategic Transactions, showed a large rise in fundraising transactions from Q3 to Q4 of last year.
Japanese firm signs definitive agreement to acquire Roivant's interests in five 'vants' initially, including new gene therapy operation, as ex-Genentech president named head of new entity.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Roivant Asia Cell Therapy Holdings Ltd.
- Hong Kong
- Pacific Rim
- Company Type
- Parent & Subsidiaries
- Roivant Sciences Inc.
- Senior Management
- John Xu, PhD, Pres.
- Contact Info
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.